Participate in Research

Clinical trials help find new methods for diagnosing, treating, managing and preventing Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease. Even the most promising scientific findings must first be proven to be safe and effective in clinical trials before they can be used as standard treatment.

Talk to your doctor to find a clinical trial that might be suitable for you or someone you care about. 

Clinical studies needing patient participants: 

Other clinical studies:

Fecal Microbiota Transplantation (FMT) Trial for Crohn’s disease 


The human body contains 10 bacterial cells for every human cell. This vast, largely unexplored bacterial community known as the microbiome, has been linked to gastrointestinal health and disease. In the case of IBD, it is thought that the immune system may be responding inappropriately to the microbiome. Therefore, it has been hypothesized that changing the microbiome may be an effective treatment for IBD.  One way to accomplish this is using Fecal Microbiota Transplantation (FMT). Fecal Microbiota Transplantation (FMT) is an innovative investigational treatment that has proven effective in the treatment of C. difficile infection. The purpose of this study is to determine whether FMT is similarly safe and effective in the treatment of mild-to-moderate Crohn’s disease. During FMT, a fecal preparation from a carefully screened, healthy stool donor is transplanted into the colon of the patient. There are multiple routes of administration (e.g., via colonoscopy, oral capsules).  In this study we will use both. 

Patients will receive a total of 8 FMT/placebo treatments in the study. 
Patients receiving FMT will be assigned a single donor. The first will be given by colonoscopy at 
Week 0, followed by 7 others given by capsules taken by mouth each week. 
At Week 8, patients are unblinded and a follow up colonoscopy is performed. 
Patients who received initially randomized to placebo can go on to have FMT in the open label phase of the study. 
 
Who is eligible?
Patients with mild to moderate Crohn’s disease
Recruiting 126 patients at three Canadian centres (Edmonton, Calgary and Hamilton)

Edmonton contact
Dr. Dina Kao: dkao@ualberta.ca
Dr. Gina Vavek: gina.vavek@albertahealthservices.ca 
Phone: 780-492-5313

Calgary contact
Dr. Humberto Jijon Humberto.jijon2@ucalgary.ca 
Gurmeet Bindra gkbindra@ucalgary.ca 
Phone: 403-210-7013 or 403-399-9790 

Hamilton Contact  
McMaster University:
Melanie Wolfe: wolfe@hhsc.ca

Drugs in lactation analysis consortium 

The goal of the study is to learn about drug safety during breastfeeding. We measure drug levels in breast milk to understand how safe they are for babies, when they are exposed through breast milk. The study involves collection of small breast milk samples between two doses of your medication and filling out a short questionnaire.

Who is eligible?

All nursing mothers who are taking one or more drug(s) on the study priority list and are able to communicate in English (For inquiry about the priority list, please contact us.). 

Person of Contact: Sholeh Ghayoori 
Email: dlac.project@sickkids.ca 
Phone: 416-813-7654 ext 205675
Website: http://www.thedlac.com/ 

teens and inflammatory bowel disease

The Family Health Lab at University of Saskatchewan is currently conducting an online study looking at the relationship between emotions and IBD-related symptoms in teens with IBD

To participate teens need to 
1. Have a parent provide consent for the teen to participate.
2. Be diagnosed with Ulcerative Colitis or Crohn's Disease 
3. Be aged 14 to 18 years old

For more information or to participate please contact
Lana McAleer-lmm249@mail.usask.ca or 306-966-5616
Teens and parents able to participate are eligible to enter a drawn for 1 of 3 $50 gift cards.

inflammatory bowel disease & quality of life 

The Queen’s University Health Psychology research team is seeking individuals diagnosed with Inflammatory Bowel Disease to participate in an ethically cleared online study examining how both positive and negative variables may impact your quality of life. Participants must be at least 18 years of age and fluent in English. The study involves completing an online survey, and if you consent, it can be followed by 2 repeats of the survey one month apart (this is important to look at how things may change over time for you). You would complete all surveys over the course of 8 weeks. To learn more about this study, please click on the following link: https://queensu.qualtrics.com/jfe/form/SV_3pIS7RTmjQRIeq1. Thank you in advance for your interest. 

Physical Activity & IBD

Understanding the relationships between physical activity and resilience on quality of life in patients with inflammatory bowel disease in comparison to those without. The study involves a 10-15 minute survey looking at physical activity, resilience levels, and quality of life.

Study Eligibility: Any person with inflammatory bowel disease who is able to read in English.

Person of Contact:
Katie Taylor
Email: 
Phone: +1 (208) 885-2007

Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis

A randomized trial of antimicrobials versus placebo in addition to fecal microbiota transplantation for the induction of remission in patients with active ulcerative colitis.

Site Investigators: Dr. Paul Moayyedi and Dr. Christine Lee

Person of Contact:
Melanie Wolfe (Research Coordinator)
Email: wolfe@hhsc.ca
Phone: 905-521-2100 x 73601

“The Pedi FETCh Research Trial: Pediatric Fecal Transplant for Ulcerative Colitis”

The Pedi FETCh Research Trial (Pediatric Fecal Transplant for Ulcerative Colitis) is the first pediatric fecal transplant study for inflammatory bowel disease in Canada, and will be the first randomized controlled trial of fecal transplant in pediatric inflammatory bowel disease in the world. The trial is being lead by Dr. Nikhil Pai, and supported by the Division of Pediatric Gastroenterology and Nutrition at McMaster Children’s Hospital. Study collaborators include Dr. Christine Lee (Division of Infectious Disease at St. Joseph’s Hospital in Hamilton), and Paul Moayyedi (Division of Adult Gastroenterology at McMaster University), with support from the Farncombe Digestive Disease Research Institute at McMaster University.

Site Investigators: Dr. N. Pai

Person of Contact:
Jelena Popov (Research Coordinator)
Email: Jolene Popov at popovj2@mcmaster.ca / Dr. Nikhil Pai at pain@mcmaster.ca
Phone: 905.521.2100 ext. 73587

More information, including eligibility, safety monitoring and frequently asked questions, is available on the McMaster website HERE

“Denosumab, a monoclonal antibody to receptor activator of nuclear factor-Kappa B ligand (RANKL), in Crohn’s disease”

Site Investigators: Dr. John K. Marshall

Persons of Contact:
Gail Cappelli at phone:(905-521-2100 Ext 76986 OR
Mitzi Lawrence (905-521-2100 Ext 20601

Project ARCC (Accelerating Research in Crohn’s and Colitis) – Developing new tools for IBD research

A study looking for individuals to give valuable feedback on from people who experience loose bowel movements in order to improve products to facilitate research and diagnostics.

Eligibility criteria: Adults suffering from Crohn’s disease, ulcerative colitis, inflammatory bowel disease (IBD) or Irritable Bowel Syndrome (IBS) who are experiencing loose bowel movements.

Compensation for complete participation.  for more information.

If you are interested in participating, contact:
Phone: 1-866-813-6354 ext 326
Email: gutresearch@dnagenotek.com

Additonal resources for clinical trials

Other Clinical studies needing patient participants: 

You may also search for clinical trials through the following sites:

 

Disclaimer
Crohn’s and Colitis Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions.

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest